Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 12/20 | 0.82 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.82 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.82 |
| ▸ | TNF | P01375 | 10/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21215174 | 0.91 | PDE4A (0.85) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098481 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6554664 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL9977590 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL3120500 | 0.90 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6966344 | 0.90 | PDE4A (0.67) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL7746632 | 0.89 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6098976 | 0.87 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL537314 | 0.87 | PDE4A (0.81) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4927794 | 0.86 | PDE4A (0.76) | PDE4APDE4BPDE4CPDE4DTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605935-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORP (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1605935-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080393-A2 | SELECTIVE CYTOKINE INHIBITORY DRUGS FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2004-09-23 | — | — | WO | disclosed |